Close Menu

NEW YORK – GeneproDx, a Santiago, Chile-based startup, is developing a multiplex quantitative PCR assay that it believes will help patients at risk of thyroid cancer avoid unnecessary surgery.

Publishing a pair of validation studies earlier this month on the firm’s ThyroidPrint assay, US and Chilean researchers showed they could successfully predict benign thyroid nodules with a sensitivity of 90 to 91 percent and a specificity of 87 to 89 percent.  

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.